What is SGMT's current stock price?

SGMT (Sagimet Biosciences Inc.) is currently trading at $7.24 with a market cap of $235.7M.

What sector is Sagimet Biosciences Inc. in?

Sagimet Biosciences Inc. (SGMT) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is SGMT a good stock to buy?

Analysts have a Buy consensus on SGMT with a price target of $8.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

SGMT Sagimet Biosciences Inc.

Healthcare

$7.24+0.00%OpenMarket Cap: $235.7M

As of 2026-05-26

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.25

P/S

0.00

EV/EBITDA

-3.99

DCF Value

$1.05

FCF Yield

-17.2%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-37.6%

ROA

-40.4%

ROIC

-47.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-10.7M	$—
Q4 null	$0.00	$-9.6M	$—
FY null	$0.00	$-51.0M	$—
Q3 null	$0.00	$-12.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$8.00

Target (Median)

$8.00

Target Range

$8.00 - $8.00

1 Strong Buy8 Buy1 Hold0 Sell0 Strong Sell

CitizensMarket Outperform

2026-05-19

Canaccord GenuityBuy

2026-05-04

GuggenheimBuy

2026-04-29

HC Wainwright & Co.Buy

2026-03-11

HC Wainwright & Co.Buy

2026-02-03

Trading Activity

Insider Trades

View All

Grauer Andreasofficer: Chief Medical Officer

SellThu May 14

Grauer Andreasofficer

SellThu May 14

Rozek Elizabethofficer: Chief Legal & Admin. Officer

SellFri Feb 20

Rozek Elizabethofficer: Chief Legal & Admin. Officer

SellFri Feb 20

Martins Eduardo Brunoofficer: Chief Medical Officer

SellFri Feb 20

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

3.63

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Peers